Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Latanoprost/phentolamine - Opus Genetics

Next Previous
Drug Profile

Latanoprost/phentolamine - Opus Genetics

Alternative Names: FDC-G; Latanoprost/phentolamine ophthalmic solution - Opus Genetics; Nyxol/latanoprost; Phentolamine/latanoprost

Latest Information Update: 24 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ocuphire Pharma
  • Developer Opus Genetics
  • Class Antiglaucomas; Erectile dysfunction therapies; Eye disorder therapies; Imidazoles; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Alpha adrenergic receptor antagonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Glaucoma

Most Recent Events

  • 22 Oct 2024 Ocuphire Pharma has merged with Opus Genetics to form Opus Genetics
  • 26 Jul 2022 No development reported - Phase-II for Glaucoma in USA (Ophthalmic) (Ocuphire pharma website, July 2022)
  • 30 Dec 2020 Latanoprost/phentolamine - Ocuphire Pharma is available for licensing as of 30 Dec 2020. https://www.ocuphire.com/

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top